{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:05:32Z","timestamp":1785769532197,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00520-025-09685-2","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:57:20Z","timestamp":1752141440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spinal analgesia in cancer pain management\u2014MASCC general practice recommendations"],"prefix":"10.1007","volume":"33","author":[{"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellar","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"9685_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers15030591","volume":"15","author":"RAH Snijders","year":"2023","unstructured":"Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ (2023) Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel) 15:591","journal-title":"Cancers (Basel)"},{"key":"9685_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2013.52.5188","volume":"32","author":"RK Portenoy","year":"2014","unstructured":"Portenoy RK, Ahmed E (2014) Principles of opioid use in cancer pain. J Clin Oncol 32:1662\u20131670","journal-title":"J Clin Oncol"},{"key":"9685_CR3","doi-asserted-by":"crossref","unstructured":"Paice JA, Bohlke K, Barton D et al (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. neccessary J Clin Oncol 41:914\u2013930","DOI":"10.1200\/JCO.22.02198"},{"key":"9685_CR4","doi-asserted-by":"crossref","unstructured":"Mercadante S (2019) The patient with difficult cancer pain. Cancers (Basel).11:565","DOI":"10.3390\/cancers11040565"},{"key":"9685_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40265-022-01780-6","volume":"82","author":"S Mercadante","year":"2022","unstructured":"Mercadante S (2022) Cancer pain treatment strategies in patients with cancer. Drugs 82:1357\u20131366","journal-title":"Drugs"},{"key":"9685_CR6","first-page":"1473","volume":"23","author":"B Afsharimani","year":"2015","unstructured":"Afsharimani B, Kindl K, Good P, Hardy J (2015) Pharmacological options for the management of refractory cancer pain-what is the evidence? Support Care Cancer 23:1473\u20131478","journal-title":"Support Care Cancer"},{"key":"9685_CR7","doi-asserted-by":"crossref","unstructured":"Mercadante S, Bruera E (2016) Opioid switching in cancer pain: from the beginning to nowadays. E.Crit Rev Oncol Hematol 99:241\u20138","DOI":"10.1016\/j.critrevonc.2015.12.011"},{"key":"9685_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3233\/BMR-1998-10203","volume":"10","author":"PS Staats","year":"1998","unstructured":"Staats PS (1998) Cancer pain: beyond the ladder. J Back Musculosk Rehab 10:69\u201380","journal-title":"J Back Musculosk Rehab"},{"key":"9685_CR9","first-page":"E414","volume":"25","author":"D Denis","year":"2022","unstructured":"Denis D, Rui D, Carvajal G, Aubrun F, Eldabe S (2022) Rationale and recent advances in targeted drugdelivery for cancer pain: is it time to change theparadigm? Pain Physician 25:E414\u2013E425","journal-title":"Pain Physician"},{"key":"9685_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ner.12263","volume":"17","author":"TR Deer","year":"2014","unstructured":"Deer TR, Caraway DL, Wallace MS (2014) A definition of refractory pain to help determine suitability for device implantation. Neuromodulation 17:711\u2013715","journal-title":"Neuromodulation"},{"key":"9685_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40122-023-00507-z","volume":"12","author":"S Mercadante","year":"2023","unstructured":"Mercadante S (2023) Refractory cancer pain and intrathecal therapy: critical review of a systematic review. Pain Ther 12:645\u2013654","journal-title":"Pain Ther"},{"key":"9685_CR12","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1200\/JCO.2003.99.079","volume":"21","author":"TS Smith","year":"2003","unstructured":"Smith TS, Staats PS (2003) Reply to commentaries on \u201cRandomized clinical trial of an implantable drug delivery system compared to comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.\u201d J Clin Oncol 21:2802\u20132803","journal-title":"J Clin Oncol"},{"key":"9685_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamaoncol.2022.2150","volume":"8","author":"J Arthur","year":"2022","unstructured":"Arthur J, Bruera E (2022) Managing cancer pain in patients with opioid use disorder or nonmedical opioid use. JAMA Oncol 8:1104\u20131105","journal-title":"JAMA Oncol"},{"key":"9685_CR14","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","volume":"20","author":"TJ Smith","year":"2002","unstructured":"Smith TJ, Staats PS, Pool G et al (2002) Randomized clinical trial of an implantable drug delivery system compared to conprehensive medical management for refractory cancer pain. Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040\u20134049","journal-title":"J Clin Oncol"},{"key":"9685_CR15","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/papr.13273","volume":"23","author":"YL Hsieh","year":"2023","unstructured":"Hsieh YL, Chen HY, Lin CR, Wang CF (2023) Efficacy of epidural analgesia for intractable cancer pain: a systematic review. Pain Pract 23:956\u2013969","journal-title":"Pain Pract"},{"key":"9685_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.36076\/ppj.2024.27.79","volume":"27","author":"JM Park","year":"2024","unstructured":"Park JM (2024) Analgesic efficacy of epidural patient-controlled analgesia on cancer pain: a retrospective observational study. Pain Physician 27:79\u201388","journal-title":"Pain Physician"},{"key":"9685_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/0304-3959(96)03161-2","volume":"67","author":"E Kalso","year":"1996","unstructured":"Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A (1996) Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 67:443\u2013449","journal-title":"Pain"},{"key":"9685_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0885-3924(05)80005-3","volume":"5","author":"P Nitescu","year":"1990","unstructured":"Nitescu P, Appelgren L, Linder LE et al (1990) Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage 5:18\u201326","journal-title":"J Pain Symptom Manage"},{"key":"9685_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00002508-199803000-00003","volume":"14","author":"P Dahm","year":"1998","unstructured":"Dahm P, Nitescu P, Appelgren L, Curelaru I (1998) Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and\/or bupivacaine in refractory nonmalignant pain: a comparison between the epidural and the intrathecal approach with externalized or implanted catheters and infusion pumps. Clin J Pain 14:4\u201316","journal-title":"Clin J Pain"},{"key":"9685_CR20","doi-asserted-by":"crossref","unstructured":"Ruppen W, derry S, McQuay H, Moore A (2007) Infection rates associated with epidural indwelling catheters for seven days or longer: systematic review and meta-analysis. BMC Palliat Care Apr 4:6:3","DOI":"10.1186\/1472-684X-6-3"},{"key":"9685_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00000542-200003000-00018","volume":"92","author":"WC Ummenhofer","year":"2000","unstructured":"Ummenhofer WC, Arends RH, Shen DD, Bernards CM (2000) Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 92:739\u2013753","journal-title":"Anesthesiology"},{"key":"9685_CR22","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1097\/j.pain.0000000000001957","volume":"161","author":"K Ma","year":"2020","unstructured":"Ma K, Jin Y, Wang L et al (2020) Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain 161:2502\u20132510","journal-title":"Pain"},{"key":"9685_CR23","doi-asserted-by":"publisher","unstructured":"Deer TR, Hayek SM, Grider JS et al (2024) The Polyanalgesic Consensus Conference (PACC): Updates on Clinical Pharmacology and Comorbidity Management in Intrathecal Drug Delivery for Cancer Pain. https:\/\/doi.org\/10.1016\/j.neurom.2024.08.006","DOI":"10.1016\/j.neurom.2024.08.006"},{"key":"9685_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.critrevonc.2011.05.007","volume":"82","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G, Gebbia V (2012) Spinal analgesia for advanced cancer patients: an update. Crit Rev Oncol Hematol 82:227\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"key":"9685_CR25","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1213\/01.ANE.0000149045.24425.68","volume":"100","author":"S Mercadante","year":"2005","unstructured":"Mercadante S, Ferrera P, Villari P, Arcuri E (2005) Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg 100:1540","journal-title":"Anesth Analg"},{"key":"9685_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002508-200109000-00009","volume":"17","author":"K Hildebrand","year":"2001","unstructured":"Hildebrand K, Elsberry D, Deer T (2001) Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain 17:239\u2013244","journal-title":"Clin J Pain"},{"key":"9685_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00000542-199202000-00004","volume":"76","author":"M Sj\u00f6berg","year":"1992","unstructured":"Sj\u00f6berg M, Karlsson PA, Nordborg C et al (1992) Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology 76:173\u2013186","journal-title":"Anesthesiology"},{"key":"9685_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00000542-199402000-00008","volume":"80","author":"M Sj\u00f6berg","year":"1994","unstructured":"Sj\u00f6berg M, Nitescu P, Appelgren L, Curelaru I (1994) Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg\/ml. Anesthesiology 80:284\u2013297","journal-title":"Anesthesiology"},{"key":"9685_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3959(98)00118-3","volume":"79","author":"S Mercadante","year":"1999","unstructured":"Mercadante S (1999) Problems of long-term spinal opioid treatment in advanced cancr patients. Pain 79:1\u201313","journal-title":"Pain"},{"key":"9685_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.291.1.63","volume":"291","author":"PS Staats","year":"2004","unstructured":"Staats PS, Yearwood T, Charapata S et al (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291:63\u201370","journal-title":"JAMA"},{"key":"9685_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.neurom.2023.11.009","volume":"27","author":"J Sorrieul","year":"2024","unstructured":"Sorrieul J, Robert J, Blanchet A et al (2024) Physicochemical stability study of the morphine-bupivacaine-ziconotide association. Neuromodulation 27:1149\u20131163","journal-title":"Neuromodulation"},{"key":"9685_CR32","first-page":"784","volume":"20","author":"TR Deer","year":"2019","unstructured":"Deer TR, Pope JE, Hanes MC, McDowell GC (2019) Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options 20:784\u2013798","journal-title":"Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options"},{"key":"9685_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40120-015-0035-z","volume":"4","author":"AB de la Calle Gil","year":"2015","unstructured":"de la Calle Gil AB, Pena Vergara I, Cormane Bornacelly MA, Pajuelo GA (2015) Intrathecal ziconotide and morphine for pain relief: a case series of eight patients with refractory cancer pain, including five cases of neuropathic pain. Neurol Ther 4:159\u2013168","journal-title":"Neurol Ther"},{"key":"9685_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pain.2011.10.002","volume":"153","author":"I Alicino","year":"2012","unstructured":"Alicino I, Giglio M, Manca F, Bruno F, Puntillo F (2012) Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 153:245\u2013249","journal-title":"Pain"},{"key":"9685_CR35","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2147\/JPR.S504556","volume":"18","author":"E Bulat","year":"2025","unstructured":"Bulat E, Chaturvedi R, Johnson P, Rakesh N, Gulati A (2025) The addition of intrathecal clonidine to reduce medication-related side-effects in cancer pain: a retrospective cohort study. J Pain Res 18:1503\u20131509","journal-title":"J Pain Res"},{"key":"9685_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1526-4637.2002.02014.x","volume":"3","author":"SJ Hassenbusch","year":"2002","unstructured":"Hassenbusch SJ, Gunes S, Wachsman S, Willis KD (2002) Intrathecal clonidine in the treatment of intractable pain: a phase I\/II study. Pain Med 3:85\u201391","journal-title":"Pain Med"},{"key":"9685_CR37","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/j.1526-4637.2011.01262.x","volume":"12","author":"S Broghan","year":"2011","unstructured":"Broghan S, Winter NB (2011) Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med 12:1758\u20131768","journal-title":"Pain Med"},{"key":"9685_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/AJP.0b013e3181565d17","volume":"23","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Intravaia G, Villari P (2007) Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 23:793\u2013837","journal-title":"Clin J Pain"},{"key":"9685_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ner.13517","volume":"24","author":"JE Sindt","year":"2021","unstructured":"Sindt JE, Odell DW, Tariq R et al (2021) Initial intrathecal dose titration and predictors of early dose escalation in patients with cancer using a 100:1 oral to intrathecal morphine conversion ratio. Neuromodulation 24:1157\u20131166","journal-title":"Neuromodulation"},{"key":"9685_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1399-6576.1991.tb03237.x","volume":"35","author":"M Sj\u00f6berg","year":"1991","unstructured":"Sj\u00f6berg M, Appelgren L, Einarsson S (1991) Long-term intrathecal morphine and bupivacaine in \u201crefractory\u201d cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 35:30\u201343","journal-title":"Acta Anaesthesiol Scand"},{"key":"9685_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0304-3959(93)90191-Q","volume":"55","author":"RT Van Dongen","year":"1993","unstructured":"Van Dongen RT, Crul BJ, De Bock M (1993) Long-term intrathecal infusion of morphine and morphine\/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55:119\u2013123","journal-title":"Pain"},{"key":"9685_CR42","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1213\/ANE.0000000000002903","volume":"126","author":"G Carvajal","year":"2018","unstructured":"Carvajal G, Dupoiron D, Seegers V (2018) Intrathecal drug delivery systems for refractory pancreatic cancer pain: observational follow-up study over an 11-year period in a comprehensive cancer center. Anesth Analg 126:2038\u20132046","journal-title":"Anesth Analg"},{"key":"9685_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1213\/ANE.0000000000004425","volume":"130","author":"L Stearns","year":"2020","unstructured":"Stearns L, Abd-Elsayed A, Perruchoud C et al (2020) Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesth Analg 130:289\u2013297","journal-title":"Anesth Analg"},{"key":"9685_CR44","doi-asserted-by":"crossref","unstructured":"Zheng S, H e L, Yang X, Yang Z (2017) Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore) 96","DOI":"10.1097\/MD.0000000000006354"},{"key":"9685_CR45","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.neurom.2021.12.004","volume":"26","author":"C Perruchoud","year":"2023","unstructured":"Perruchoud C, Dupoiron D, Papi B, Calabrese A, Brogan SE (2023) Management of cancer-related pain with intrathecal drug delivery: a systematic review and meta-analysis of clinical studies. Neuromodulation 26:1142\u20131152","journal-title":"Neuromodulation"},{"key":"9685_CR46","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.neurom.2022.03.003","volume":"26","author":"R Duarte","year":"2023","unstructured":"Duarte R, Copley S, Nevitt et al (2023) Effectiveness and safety of intrathecal drug delivery systems for the management of cancer pain: a systematic review and meta-analysis. Neuromodulation 26:1126\u20131141","journal-title":"Neuromodulation"},{"issue":"584","key":"9685_CR47","first-page":"44","volume":"22","author":"A Kowal","year":"1997","unstructured":"Kowal A, Staats PS, Schweitzer TW et al (1997) Intractable cancer pain: a new technique for attack in a patient with an implanted intrathecal infusion pump. Reg Anesth 22(584):44","journal-title":"Reg Anesth"},{"key":"9685_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","volume":"20","author":"EM Delhaas","year":"2020","unstructured":"Delhaas EM, Huygen FJPM (2020) Complications associated with intrathecal drug delivery systems. BJA Educ 20:51\u201357","journal-title":"BJA Educ"},{"key":"9685_CR49","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/j.1526-4637.2011.01262.x","volume":"12","author":"S Broghan","year":"2011","unstructured":"Broghan S, Winter NB (2011) Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med 12:1758\u20131768","journal-title":"Pain Med"},{"key":"9685_CR50","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1089\/jpm.2020.0487","volume":"23","author":"CZ Chou","year":"2020","unstructured":"Chou CZ, Hopkins TJ, Badiola I et al (2020) Top ten tips palliative care clinicians should know about interventional pain and procedures. J Palliat Med 23:1386\u20131391","journal-title":"J Palliat Med"},{"key":"9685_CR51","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1097\/j.pain.0000000000001957","volume":"161","author":"K Ma","year":"2020","unstructured":"Ma K, Jin Y, Wang L (2020) Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain 161:2502\u20132510","journal-title":"Pain"},{"key":"9685_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1067\/S1526-5900(03)00730-2","volume":"4","author":"RL Rauck","year":"2003","unstructured":"Rauck RL, Cherry D, Boyer MF et al (2003) Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 4:441\u2013447","journal-title":"J Pain"},{"key":"9685_CR53","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1097\/j.pain.0000000000002232","volume":"162","author":"S Mercadante","year":"2021","unstructured":"Mercadante S (2021) Intrathecal patient-controlled analgesia has nothing to do with breakthrough cancer pain. Pain 162:1586","journal-title":"Pain"},{"key":"9685_CR54","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1097\/j.pain.0000000000000721","volume":"157","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Portenoy RK (2016) Breakthrough cancer pain: twenty-five years of study. Pain 157:2657\u20132663","journal-title":"Pain"},{"key":"9685_CR55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jpainsymman.2005.04.014","volume":"30","author":"S Mercadante","year":"2005","unstructured":"Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S (2005) Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 30:485\u2013491","journal-title":"J Pain Symptom Manage"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09685-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:30:29Z","timestamp":1757223029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09685-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9685"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09685-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peter Staats: Advisory Board AIS,Research Saluda, Nalu, Biotronik, Chief Medical Officer electroCore, Chief Medical Advisor SPR therapeutics, Royalties for patent Averitas Sebastiano Mercadante: role of Editor for SCC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"674"}}